Searching for Primaries in Patients with NET of Unknown Primary and Clinically Suspected NET: Evaluation of Ga-68 DOTATOC PET/CT and In-111 DTPA Octreotide SPECT/CT

  • Nils F Schreiter Charité, Department of Radiology and Nuclear medicine Augustenburger Platz 1, 13353 Berlin

Abstract

Aim:

To evaluate the clinical efficacy of In-111 DTPA octreotide SPECT/CT and Ga-68 DOTATOC PET/CT for detection of primary tumors in patients with either neuroendocrine tumor of unknown primary (NETUP) or clinically suspected primary NET (SNET).

Material and Methods:

A total of 123 patients were included from 2006 to 2009, 52 received Ga-68 DOTATOC PET/CT (NETUP, 33; SNET, 19) and 71 underwent In-111 DTPA octreotide SPECT/CT (50; 21). The standard of reference included histopathology or clinical verification based on follow-up examinations.

Results:

In the NETUP group Ga-68 DOTATOC detected primaries in 15 patients (45.5%) and In-111 DTPA octreotide in 4 patients (8%) (p<0.001); in the SNET group, only 2 primaries could be detected, all by Ga-68 DOTATOC. In patients with NETUP, primary tumors could be found significantly more often than in patients with SNET (p=0.01). Out of these 21 patients 14 patients were operated.

Conclusion:

Ga-68 DOTATOC PET/CT is preferable to In-111 DTPA octreotide SPECT/CT when searching for primary NETs in patients with NETUP but should be used with caution in patients with SNET.

Published
2014-10-26
How to Cite
Schreiter, N. F. (2014). Searching for Primaries in Patients with NET of Unknown Primary and Clinically Suspected NET: Evaluation of Ga-68 DOTATOC PET/CT and In-111 DTPA Octreotide SPECT/CT. Radiology and Oncology, 48(4). Retrieved from https://www.radioloncol.com/index.php/ro/article/view/2047
Section
Nuclear medicine